Baicalin, a metabolite of baicalein with antiviral activity against dengue virus

Ehsan Moghaddam1, Boon-Teong Teoh1, Sing-Sin Sam1, Rafidah Lani1, Pouya Hassandarvish1, Zamri Chik2, Andrew Yueh3, Sazaly Abubakar1 & Keivan Zandi1

1Tropical Infectious Disease Research and Education Center, Department of Medical Microbiology Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia, 2Department of Pharmacology, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia, 3Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli 350, Taiwan, ROC.

Baicalin, a flavonoid derived from Scutellaria baicalensis, is the main metabolite of baicalein released following administration in different animal models and human. We previously reported the antiviral activity of baicalein against dengue virus (DENV). Here, we examined the anti-DENV properties of baicalin in vitro, and described the inhibitory potentials of baicalin at different steps of DENV-2 (NGC strain) replication. Our in vitro antiviral experiments showed that baicalin inhibited virus replication at IC50 = 13.5 ± 0.08 µg/ml with SI = 21.5 following virus internalization by Vero cells. Baicalin exhibited virucidal activity against DENV-2 extracellular particles at IC50 = 8.74 ± 0.08 µg/ml and showed anti-adsorption effect with IC50 = 18.07 ± 0.2 µg/ml. Our findings showed that baicalin as the main metabolite of baicalein exerting in vitro anti-DENV activity. Further investigations on baicalein and baicalin to deduce its antiviral therapeutic effects are warranted.

Dengue virus (DENV) is an enveloped RNA virus belonging to the Flaviviridae family. There are four distinct serotypes, DENV-1, DENV-2, DENV-3, and DENV-4. Dengue virus can cause a range of diseases from asymptomatic infection to mild dengue fever (DF) or severe dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS)1,2. DENV is transmitted principally in a cycle that involves humans and mosquito vectors, Aedes aegypti and Aedes albopictus. All DENV serotypes are widespread geographically in tropical and subtropical regions of the world, causing life-threatening disease imposing considerable health and economic burden. Currently, there is no approved vaccine or antiviral agents against clinical dengue necessitating prompt strategies to design effective antiviral strategies against this infection.

In recent years, many investigators focus on plants and their derivatives to develop new antiviral drugs3–5. Some phytochemicals have been shown to have therapeutic applications against genetically and functionally diverse viruses6–9. Flavonoids are polyphenolic plant metabolites with numerous biological activities and low toxicity. More than 5000 natural flavonoids have been identified in plants or various dietary sources that are presumed to have potential health benefits4. Antiviral properties of flavonoids, a group of plant polyphenolics have been reported against different viruses including DENVs4,6–11. Recently, we showed that baicalein, a flavonoid belonging to the flavones subgroup (Figure 1A) exhibited significant antiviral effects against in vitro replication of DENV-2 in Vero cells, functioning at different stages of virus replication9. Baicalein (5, 6, 7-trihydroxyflavone) is a flavonoid originally isolated from Scutellaria baicalensis, a Chinese medicinal plant with various biological properties. Baicalin (5,6-dihydroxy-7-O-glucuronide flavone) is also a flavonoid (Figure 1B) presents in the roots of S.baicalensis Baicalein is metabolized and converted mainly to baicalin following intake to animals and humans12–14.

It has also been shown that ~90% of baicalein administered is metabolized to baicalin15, and hence, it is necessary to investigate the role of baicalin in any particular medical condition.

Here, we determined the antiviral activities of baicalin at different stages of DENV replication in Vero cells and on DENV replicon cell line. We showed that baicalin interferes and inhibits DENV-2 in vitro replication at various stages of the virus replication cycle.

Results
Cytotoxic activity of baicalin. Cytotoxicity assay was performed to determine the non-toxic concentrations of baicalin against Vero cells using the MTS assay. We found that the half maximal cytotoxic concentration (CC50)
of baicalin was 290.9 μg/ml. At a concentration of 62.5 μg/ml, the viability of baicalin-treated Vero cells was >90% compared to vehicle control indicating that the concentration could be considered as the maximum non-toxic dose (MNTD) of baicalin for Vero cells (Figure 2). Therefore, 50 μg/ml was chosen as the highest concentration of baicalin in all antiviral assays that was lower than the maximum non-toxic dose MNTD of baicalin.

Inhibitory effect of baicalin on BHK-DENV replicon cell line. To determine whether baicalin exerts antiviral functions at the intracellular stages of DENV-2 replication, we studied the effect of the compound on BHK-DENV subgenomic replicon cell line that encodes only non-structural viral proteins. Our results showed that baicalin inhibited replication of DENV subgenomic replicon (Figure 3). Baicalin exhibited a significant antiviral activity with IC\textsubscript{50} = 14.9 μg/ml ± 0.07 against intracellular DENV-2 intracellular replicon by targeting non-structural protein(s) of virus. This observation corroborated the data obtained in the time-of-drug-addition studies.

Baicalin inhibits DENV-2 replication \textit{in vitro} in a dose-dependent manner. The \textit{in vitro} anti-DENV activity of baicalin was evaluated by DENV foci reduction assay and virus yield reduction assay. We observed that baicalin inhibited DENV-2 infectious foci in a dose-dependent manner (Figure 4A). At 50 μg/ml of baicalin, DENV-2-induced foci formation was completely inhibited (Figure 4C). The antiviral effect of baicalin was further confirmed by virus yield reduction assay using q RT-PCR (Figure 4B). On the first day post infection the DENV RNA copy number was dropped from 609 copies (non-treated DENV infected cells) to 106 copies in the treated cells with 50 μg/ml of baicalin which is equal to 72.2% ± 0.5 inhibition of virus yield production (Figure 4A). Interestingly, in the second day post infection the copy number of DENV RNA in non-treated wells (15638 copies) has dropped to 1829 copies in the presence of 50 μg/ml of baicalin (78.3% ± 0.7 inhibition). The result of virus yield assay for the third day post infection showed the significant DENV replication inhibition by dropping the DENV RNA copy number from 422905 copies in the non-treated cells to 10572 copies in the treated cells with 50 μg/ml of baicalin, equal to 97.5 ± 0.5 DENV replication inhibition (Figure 4C).

Baicalin exerts virucidal activity against free DENV-2 particles. We have previously shown that baicalein exerts significant virucidal activity against extracellular DENV-2 particles\textsuperscript{3}. Hence, in the present study we examined whether baicalin, the main metabolite of baicalein could also inactivate extracellular DENV-2 particles and prevent subsequent infection. Baicalin was pre-incubated with the virus suspension and diluted to sub-therapeutic concentrations prior to infecting the respective host cell. Our results showed that baicalin inactivated DENV-2 virions (Figure 5), and importantly, baicalin exhibited a maximum function at an IC\textsubscript{50} of 8.74 ± 0.08 μg/ml. However, it was shown that 25 μg/ml of baicalin which was lower than MNTD of the compound was able to exhibit 96.1% ± 1
reduction for DENV-2 infectious foci number (Figure 5). The data suggested that baicalin directly inactivates free DENV-2 particles and neutralize their infectivity attributes.

Baicalin exerts inhibitory effect by acting against DENV-2 cell attachment but not entry. Next, to further characterize the antiviral mechanism(s) of baicalin, we investigated the effect of the compound against virus attachment to host cell receptors. The change in temperature between 4°C (permitting virus binding but not entry) and 37°C (facilitating virus entry/penetration) allows examination of the effect of the drug on each specific cellular event. Our study showed that baicalin prevented attachment of DENV-2 to the Vero cells (Figure 6) at IC50 518.07±0.2 mg/ml. Figure 6C showed the 75.2% reduction in number of DENV foci due to interruption with DENV attachment to the cells.

To further investigate whether baicalin retained its effects against cellular penetration stage of DENV-2, we facilitated viral binding to cell receptors at 4°C followed by inactivation of unabsorbed viruses. Subsequently, the adsorbed viruses were facilitated to penetrate the host cell membrane by rendering a temperature shift to 37°C in the presence or absence of the baicalin. Our experiments did not reveal any significant activity by baicalin against penetration of attached DENV-2 to Vero cells (data not shown). Moreover, there was no significant inhibitory activity for baicalin against DENV-2 replication efficiency when it was used in pre-treatment mode (data not shown).

Antiviral activity of baicalin after virus entry to the host cell. To investigate the inhibitory effect of baicalin against intracellular DENV-2 replication, the infected Vero cells were treated with increasing concentrations of baicalin. Our investigation showed that baicalin at a concentration of 50 µg/ml inhibited DENV-2 replication to 99% (Figure 7) with IC50 513.50±0.08 µg/ml.

Discussion
Dengue virus is the most common human arbovirus with ~390 million estimated cases per year and ~96 million symptomatic patients18. The greatest number of dengue cases occurs in Asia and Latin America, but the disease reportedly spreads across the different unaffected parts of the world due to various factors such as climate...
change, increased travelling and unplanned urbanization19. To date, there is no licensed vaccine or effective antiviral therapy for prevention and treatment of dengue infection. Therefore, drug discovery against dengue virus remains a priority.

An efficient and safe antiviral agent for dengue virus should ideally have the potential to decrease the number of infected individuals with clinical presentations, and also protect travellers who travel to dengue endemic regions. Therefore, development of effective antidengue drug with the above mentioned criteria assumes significant priority20. Among the different compounds with various biological benefits including antiviral activity, flavonoids represent the target of interest to drug discovery scientists21–23.

Baicalin, a flavonoid isolated mainly from the roots of *Scutellaria baicalensis*, is also the main metabolite of baicalein. In our previous study, we found that baicalein exerts antiviral activity against DENV-2 in Vero cells by different mechanisms3. We have also reported the anti-dengue activity of an extract of the roots of *Scutellaria baicalensis* as the main natural source for baicalein and baicalin against *in vitro* replication of dengue virus previously24. It was demonstrated that baicalein after administration to the different animals and human converts it to baicalin as its main metabolite12,13,25. However, the conversion of baicalin to baicalein occurs during digestion by the removal of a glycoside moiety by β-glucoronidase15,26. β-glucoronidase can be found as a lysosomal enzyme mainly available in the lumen of intestine and also produced by certain intestinal commensal bacteria15,27 but still there is no evidence related to that conversion in cell culture. Here, we report that baicalin, the main metabolite of baicalein inhibits the replication of DENV-2 in Vero cells through various mechanisms. In DENV-2 subgenomic replicon system, baicalin also showed inhibitory activity that indicates its credentials against DENV intracellular replication by potentially affecting viral genes. Our data from the replicon assay was in concordance with results of foci forming assay and virus-yield study. DENV yield in Vero cells was significantly reduced after exposing doses of baicalin lower than its MNTD.

Our studies showed that baicalin did not affect DENV replication when it was added to the Vero cells prior to virus infection. Thus, it is unlikely that it exerts antiviral activity by directly affecting the host’s cell. We showed that baicalin affects DENV-2 replication when it was added after virus entry which is consistent with our previous finding on baicalein anti-dengue activity with IC50 = 6.46 μg/ml4. Although, here we showed that baicalin exhibited intracellular antiviral activity against DENV-2 with IC50 = 13.50 μg/ml its SI value however, remained 21.5, which is more significant as compared to its counterpart value for baicalein (SI = 17.8)9.

Figure 5 | Virucidal activity of baicalin on DENV-2 free particles. Foci forming unit reduction assay (FFURA) on Vero cells was performed to evaluate the virucidal activity of baicalin on DENV-2 extracellular particles. Virucidal activity of 50 μg/ml of baicalin (B); or with 25 μg/ml of baicalin (C) or without baicalin (D) using DENV foci immunostaining method on the day 4 post infection were shown. It is shown that 50 μg/ml of baicalin can inactivate more than 99% of DENV-2 free particles (A). Data from triplicate assays for three independent experiments were plotted using Graph Pad Prism Version 5 (Graph Pad Software Inc., San Diego, CA.).
On the other hand, results of the virus inactivation assay suggests that baicalin could interact with extracellular DENV particles and inactivate them with SI value equal to 33.2. Accordingly, we recently showed that the extract of *S. baicalensis* and pure baicalein also exerted direct virucidal activity against DENV extracellular particles at SI values equal to 9.5 and 74.3, respectively. This property might confer baicalein and baicalin the potentials to reduce circulating DENV particles during viremic phase of the disease, which is important to minimize disease severity. Besides, it also significantly diminishes viral transmission from infected individuals to mosquitoes during blood meal.

Our data also suggest that DENV infection was significantly impaired if baicalin is present at the time of adsorption (SI = 16). However, baicalin did not affect viral internalization following adsorption to the cell surface. These results suggest that baicalin may exert its antiviral activity by inactivation of virus particles at high concentrations and possibly by interference with DENV adsorption to Vero cells at non-virucidal concentrations. However, the precise mechanism by which baicalin inhibits the DENV binding process remains to be elucidated.

Owing to the influence made by baicalin affecting the different stages of DENV replication, further studies may be required to reveal the specific antiviral target(s) of the compound. Therefore, we currently continue our efforts to investigate the molecular and intracellular pathways the compound targets, especially especially identification of target viral genes and cellular elements such as cytokines that could play a role in facilitating its anti-DENV functions.

In conclusion, we convincingly showed that baicalin the main metabolite of baicalein, a dengue virus replication inhibitor also exerts a antiviral activity against DENV-2 *in vitro* replication. Baicalin interferes with intracellular virus replication besides inactivation of free DENV particles and affects viral attachment step of DENV to host cells. Insights into the precise mechanisms whereby baicalin exerts its anti-dengue activity could lead to rational designing of more effective and selective inhibitors of DENV. Our finding of antiviral properties of baicalin supports further investigations directed on anti-DENV drug development.

**Methods**

**Cells and virus.** C6/36 mosquito cells and Vero (African green monkey kidney) cells (ATCC) were cultured and maintained in Eagle’s Minimum Essential Medium (EMEM, Gibco, NY, USA) supplemented with 10% fetal bovine serum (FBS) (Gibco, NY, USA). C6/36 and Vero cells were incubated at 28 °C and 37 °C, respectively in a 5% CO2 humidified atmosphere. BHK-DENV replicon cell line was cultured and maintained in Dulbecco’s Minimum Essential Medium (DMEM, Gibco, NY, USA) containing 2% FBS and 1 mg/ml G418.
In this study dengue virus type-2 (DENV-2) New Guinea C strain (NGC) was used. The virus was maintained at the Virology laboratory of the Tropical Infectious Disease Research and Education Center (TIDREC), Faculty of Medicine, University of Malaya (Kuala Lumpur, Malaysia). C6/36 cells were infected with DENV-2 and supernatant consisting of viruses were harvested after observation of cytopathic effect (CPE) on day seven post infection. Virus stock to the study was prepared and titrated on Vero cells using the focus forming assay as previously described29 and stored at 2°C until needed. At the time of virus propagation and antiviral assays, the concentration of FBS was reduced to 2%.

Flavonoid. Baicalin was purchased from Sigma Chemical Company (Sigma, St Louis, USA). The stock solution (50 mg/ml) was prepared in Dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St. Louis, MO, USA) and stored at −20°C until needed. At the time of experiment, the stock solution was serially diluted using EMEM (Gibco, NY, USA), containing 2% fetal bovine serum (FBS) and sterilized with syringe filter 0.2 μm pore size (Millipore, MA, USA).

Cell cytotoxicity assay. Cytotoxicity of baicalin against Vero cells was determined using the MTT assay as previously describe6. Briefly, a confluent monolayer of Vero cells in 96-well cell culture microplate were treated with increasing concentrations of baicalin in triplicates for 4 days equivalent to that used in the antiviral assays. After 4 days, MTT solution (Promega, Madison, WI, USA) (15 μl) was added to each well and the microplate was kept at 37°C for 4 h in a humidified atmosphere with 5% CO2. Then, solubilization/stop solution (100 μl) was added to the wells and the absorbance values of the wells were measured at 570 nm using a 96-well plate reader (TECAN, Mannendorf, Switzerland). Dose-response curve was plotted using Graph Pad Prism 5 (Graph Pad Software Inc., San Diego, CA, USA) and the half maximal cytotoxic concentration (CC50) of baicalin was determined from the plot. Results were represent as the means ± standard error of the mean (SEM) from triplicate assay from three independent experiments.

DENV replicon cell system. BHK-DENV replicon cells28 were plated at a density of 1 × 10⁴ cells/well in a tissue culture-treated white view 96-well plate (Promega). The following day, the all culture medium was replaced with DMEM containing of 2% FBS and increasing dilution of baicalin. Treated cells were then incubated for 48 h at 37°C in a 5% CO2 humidified chamber. The culture medium was decaned and cells were rinsed with PBS. Cells were lysed with 100 μl of lysis buffer (Promega), and the luciferase activity was evaluated following the manufacturer’s protocol (Promega). Triplicate wells were lysed at the time indicated and luminescence signal measured using the GloMAX 20/20 Luminometer (Promega). The luminescence signal was plotted against the log transformation of the concentration of baicalin and a sigmoidal curve fit with variable slope was created to obtain the half maximal inhibitory concentration (IC50) value using Graph Pad Prism 5 (Graph Pad Software Inc., San Diego, CA, USA, 2005). Results were represent as the means ± standard error of the mean (SEM) from triplicate assay from three independent experiments.

Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR). Extracellular DENV-2 RNAs were extracted from the supernatant of the DENV-2 infected cells using the RNA extraction kit (Qiagen, Hilden, Germany). The quantitative RT-PCR was performed by adding 1 μl of extracted DENV-2 RNA to the SensiMix SYBR green mixture (Quantace, Watford, United Kingdom) together with
50 pmol of forward (DNF) and also reverse (D2R) primers. Amplification was performed using the DNA Engine Opticon system (MJ Research/Bio-Rad, Hercules, CA) with the following thermal cycling conditions: reverse transcription at 50°C for 30 min, initial denaturation at 95°C for 10 min, followed by 45 cycles of 95°C for 15 sec, 59°C for 30 sec and 72°C for 30 sec. Melt curve analysis was subsequently performed at temperature from 60°C to 98°C to verify the assay specificity. The absolute efficiencies of viral RNA in the samples were measured with a standard curve generated with a 5-fold serially diluted viral RNA extracted from DENV-2 virus inoculum of known infectious titer.

Focus forming unit reduction assay (FFURA). Antiviral activity of baicain was determined and evaluated by measuring the reduction in the number of DENV infectious foci after treatment. Briefly, infected Vero cells which were treated with different regimes were incubated for 4 days post infection (PI) using conditioned-growth medium supplemented with 2% FBS and 1.5% camerobutyl cellodose (CMC). Virus foci were visualized as previously described. The number of DENV-2 foci was counted using a stereomicroscope and the virus titer was expressed as Foci Forming Unit (FFU). Antiviral activities of the compounds were determined by calculating the percentage of foci reduction (%RF) compared against the controls maintained in parallel using the following formula: RF (%) = (C-T) × 100/C, where C is the mean of the number of foci from triplicates treatment without compound added (vehicle control) and T is the mean of the number of foci from triplicates of each treatment measures with the respective compound. Results were represent as the means ± standard error of the mean (SEM) from triplicate assay from three independent experiments. Selectivity Index value (SI) was determined as the ratio of IC_{50} to IC_{90}.

1. Hidari, K. I. et al. Structure and anti-dengue virus activity of sulfated polysaccharide from a marine alga. Biochem. Biophys. Res. Comm. 376, 91–95 (2008).
2. Talarico, L. B. & Damonte, E. B. Interference in dengue virus adsorption and uncoating by carrageenans. Virology 363, 473–485 (2007).
3. Zandi, K. et al. Flavone enhances dengue virus type-2 (NGC strain) infectivity and replication in Vero cells. Molecules 17, 2437–2445 (2012a).
4. Huh, S. U. & Paek, K. H. Plant RNA binding proteins for control of RNA virus infection. Front Physiol 4, 397 (2013).
5. Kumar, S. & Pandey, A. K. Chemistry and Biological Activities of Flavonoids: An Overview. ScientificWorldJournal 29, 2013:1650 (2013).
6. Lyu, S. Y., Rhihm, J. Y. & Park, W. B. Antipheric activities of flavonoids against herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) in vitro. Arch. Pharm. Res. 31, 293–301 (2008).
7. Evers, D. L. et al. Human cytomegalovirus-inhibitory flavonoids: study on antiviral activity and mechanism of action. Antiviral Res. 68, 124–134 (2005).
8. Beecher, G. R. Overview of dietary flavonoids: nomenclature, occurrence and intake. J. Nutr. 133, 3248–3254 (2003).
9. Zandi, K. et al. Novel antiviral activity of baicain against dengue virus. BMC Complement Altern Med. 12, 1–9 (2012b).
10. Zandi, K. et al. Antiviral activity of four types of bioflavonoid against dengue virus type-2. Virol J. 8, 560 (2011).
11. Oezcelik, B., Orhan, I. & Toker, G. Antiviral and antimicrobial assessment of some selected flavonoids. Z. Naturforsch. C. Biosci. 61, 632 (2006).
12. Tian, S. et al. Pharmacokinetic study of baicain after oral administration in monkeys. Fitoterapia 83, 532–540 (2012).
13. Tian, S. et al. Pharmacokinetic study of baicain and its major metabolites after iv administration in dogs. JCM 3, 196–201 (2013).
14. Che, Q. et al. Studies on metabolites of baicain in human urine. Zhongguo Zhong Yao Za Zhai 26, 768 (2001).
15. Xu, G., Jou, D., Zhang, L., Guo, Q. & Zhou, C. Inhibitory effects of baicain on the influenza virus in vivo is determined by baicain in the siro. Biol. Pharm. Bull. 33, 238–243 (2010).
16. Lai, M. Y., Hsiu, S. L., Chen, C. C., Hou, Y. C. & Chao, P. D. L. Urinary pharmacokinetics of baicain, wogonin and their glycosides after oral administration of Scutellaria Radix in humans. Biol. Pharm. Bull. 26, 79–83 (2013).
17. Dou, J. et al. Effects of baicain on Sendai virus in vivo are linked to serum baicain and its inhibition of hemaglutinin-neuraminidase. Arch. Virol. 156, 793–801 (2011).
18. Bhatt, S. et al. The global distribution and burden of dengue. Nature 496, 504–507 (2013).
19. Lim, S. P. et al. Ten years of dengue drug discovery: progress and prospects. Antiviral Res. 100, 500–519 (2013).
20. Koishi, A. C., Zanello, P. R., Bianco, E. M., Bordignon, J. & Nunes Duarte dos Santos, C. Screening of dengue virus antiviral activity of marine seaweeds by an in vitro. J. Nat. Prod. 75, 587–592 (2012).
21. Michel, T., Halabalaki, M. & Skalkousis, A. L. New concepts, experimental approaches, and dereplication strategies for the discovery of novel pytotherapeutics from natural sources. Planta Med. 79, 514–532 (2013).
22. Romano, B. et al. Novel insights into the pharmacology of flavonoids. Phytother. Res. 27, 1588–96 (2013).
23. Cusinache, T. P. & Lamb, A. J. Antimicrobial activity of flavonoids. Int. J. Antimicrob. Agents 26, 343–56 (2005).
24. Zandi, K. et al. Extract of Scutellaria baicalensis inhibits dengue virus replication. BMC Complement Altern Med. 13, 98 (2013).
25. Guo, X. Y. et al. Identification of the metabolites of baicain in human plasma. J. Asian Nat Prod Res 13, 861–868 (2011).
26. Chen, S. et al. Effects of the flavonoid baicain and its metabolite baicain on androgen receptor expression, cell cycle progression and apoptosis of prostate cancer cells line. Cell Prolif. 43, 293–304 (2001).
27. Xin, W. et al. Research progress on pharmacological actions and mechanism of baicain and baicain. Curr Opin Complement Altern Med 1, e00010 (2014).
28. Yang, C. C. et al. Characterization of an efficient dengue virus replicon for development of assays of discovery of small molecules against dengue virus. Antiviral Res. 98, 228–241 (2013).
29. Wong, S. S., Abd-Jamal, J. & Abubakar, S. Antibody neutralization and viral virulence in recurring dengue virus type 2 outbreaks. Viral Immunol. 20, 359–368 (2007).
30. Wong, P. F. & Abubakar, S. High intracellular Zn^{2+} ions modulate the VHR, ZAP-70 and ERK activities of LNCAP prostate cancer cells. Cell. Mol. Biol. Lett. 13, 375–390 (2008).
31. Zai, C. K., Chow, V. T. K., Tan, H. C. & Can, Y. C. Rapid, simple-step RT-PCR typing of dengue viruses using five NS5 gene primers. J. Virol. Methods 51, 193–200 (1995).
32. Laille, M., Gerald, F. & Debitus, C. *In vitro* antiviral activity on dengue virus of marine natural products. *Cell. Mol. Life. Sci.* 54, 167–70 (1998).

**Acknowledgments**

The authors would like to thank the Ministry of Higher Education (MOHE), Malaysia, for High Impact Research (HIR) MOHE Grant (E000087-20001) and Long Range Grant Scheme (LRGS) LR001/2011F. They also would like to thank the University of Malaya for University Malaya Research Grant (UMRG) (RG383-11HTM).

**Author contributions**

Conceived and designed the experiments: K.Z., S.A.B. Performed the experiments: E.M., B.T.T., P.H., S.S.S., R.L. Analyzed the data: K.Z., S.S.B., A.Y., E.M., Z.C. Contributed essential reagents: A.Y. Wrote the manuscript: E.M., K.Z., A.Y., S.A.B. All authors reviewed the manuscript.

**Additional information**

**Competing financial interests:** The authors declare no competing financial interests.

**How to cite this article:** Moghaddam, E. *et al.* Baicalin, a metabolite of baicalein with antiviral activity against dengue virus. *Sci. Rep.* 4, 5452; DOI:10.1038/srep05452 (2014).

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder in order to reproduce the material. To view a copy of this license, visit [http://creativecommons.org/licenses/by-nc-sa/4.0/](http://creativecommons.org/licenses/by-nc-sa/4.0/)